Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial

Journal:

The Lancet Oncology

Published:

2025-10-29

DOI:

10.1016/s1470-2045(25)00470-x

Affiliations:

23

Authors:

22

Go to article

Institutions	Authors	Share
Medica Scientia Innovation Research (MedSIR), Spain	6.416667	0.29
Medical University of Vienna (MUW), Austria	6.000000	0.27
Virgen del Rocío University Hospital, Spain	1.000000	0.05
Hospital Quirónsalud Sagrado Corazón, Spain	1.000000	0.05
Dexeus University Hospital, Spain	1.000000	0.05
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.05
Danube Private University (DPU), Austria	1.000000	0.05
Arnau de Vilanova University Hospital (HUAV), ICS, Spain	0.750000	0.03
CEU Cardinal Herrera University, Spain	0.750000	0.03
Hospital Universitario Ramón y Cajal, Spain	0.458333	0.02
IOB Institute of Oncology, Spain	0.333333	0.02
Hospital Beata María Ana, Spain	0.333333	0.02
Paracelsus Medical University (PMU), Austria	0.333333	0.02
Salzburg Cancer Research Institute (SCRI), Austria	0.333333	0.02
Cancer Cluster Salzburg (CCS), Austria	0.333333	0.02
Hospital Prof. Doutor Fernando Fonseca EPE (HFF), Portugal	0.333333	0.02
International Breast Cancer Center (IBCC), Spain	0.125000	0.01
Pangaea Oncology SA, Spain	0.125000	0.01
University Hospital General de Catalunya - Quirónsalud Group, Spain	0.125000	0.01
European University of Madrid (UEM), Spain	0.125000	0.01
Hospital Universitario Torrejón, Spain	0.125000	0.01

Interested in Oncology and Carcinogenesis?